AIM: To evaluate the efficacy of the improved thrombospondin mimetic peptide @entity50530 in a @entity19 model of @entity31 . METHODS: The dextran @entity2397 (DSS) was used for the induction of @entity1960 in both @entity38207 deficient ( @entity38207 (-/-)) and @entity164 ( @entity164 ) @entity19 during 7 d. While @entity19 were receiving the DSS dissolved in the drinking water, the @entity50530 peptide was dissolved in sterile 5% @entity413 solution and delivered using mini pumps subcutaneously implanted. Plasma samples were analyzed for @entity777 by ELISA assay and colonic tissues were harvested, fixed and processed for histological evaluation. Immunohistochemistry using antibodies for the detection of @entity5231 and MECA in endothelial cells was performed. @entity32 was graded in colonic sections and the number of microvessels in each lesion was assessed. Activation of @entity10433 ( @entity10433 ) in colonic samples was quantified by immunohistochemistry and Western blotting using antibodies against total @entity10433 and phosphorylated @entity10433 (pSTAT3) (Ser727). RESULTS: Treatment with @entity50530 considerably diminished the inflammatory response in @entity164 and @entity38207 (-/-) @entity19 (P < 0.0001 in both groups vs control). Identification of blood vessels highlighted by @entity5231 /MECA immunohistochemistry, showed significantly reduced vessel counts in colitic lesions of @entity164 and @entity38207 (-/-) @entity19 treated with @entity50530 ( @entity38207 (-/-) controls/ @entity38207 (-/-) treated, P = 0.0002; @entity164 controls/ @entity164 treated, P = 0.0005). Consistently, @entity777 was significantly diminished in plasma samples of @entity38207 (-/-) and @entity164 treated with the peptide when compared to the control @entity19 (P = 0.0002 and P = 0.0148, respectively). pSTAT3 positive cells were quantified in @entity164 and @entity38207 (-/-) treated with @entity50530 . A significant decrease in positive cells for pSTAT3 was observed in treated @entity19 ( @entity38207 (-/-) controls/ @entity38207 (-/-) treated, P = 0.0089; @entity164 / @entity164 treated, P = 0.0110). These results were confirmed by Western blotting analyses showing lower levels of pSTAT3 in colitic lesions from @entity19 treated with the peptide @entity50530 . CONCLUSION: These findings indicate that the new peptide @entity50530 ameliorates @entity32 and angiogenesis and might be a therapeutic alternative in @entity8787 and @entity32 .

Thrombospondin peptide @entity50530 inhibits XXXX and angiogenesis in a @entity1960 model.

@entity32 :: ('MESH:D007249', 'Disease') :: ['Inflammation', 'inflammation', 'inflammatory diseases'] @entity50530 :: ('MESH:C554676', 'Chemical') :: ['ABT-898', 'ABT898'] @entity19 :: ('10090', 'Species') :: ['mice', 'murine'] @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis'] @entity2397 :: ('MESH:C012036', 'Chemical') :: ['sodium sulfate'] @entity10433 :: ('20848(Tax:10090)', 'Gene') :: ['STAT3', 'signal transducer and activator of transcription 3'] @entity1960 :: ('MESH:D003092', 'Disease') :: ['colitis'] @entity38207 :: ('108314(Tax:10090)', 'Gene') :: ['TSP-1'] @entity777 :: ('16193(Tax:10090)', 'Gene') :: ['interleukin (IL)-6', 'IL-6'] @entity164 :: ('MESH:D017827', 'Disease') :: ['WT', 'wild type'] @entity5231 :: ('18613(Tax:10090)', 'Gene') :: ['CD31'] @entity8787 :: ('MESH:C535541', 'Disease') :: ['IBD'] @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']
@entity32 :: (MESH:D007249,Disease) :: ['inflammation']
